Perrigo (PRGO) Cash from Financing Activities (2013 - 2026)
Perrigo (PRGO) reported Cash from Financing Activities of -$45.3 million for Q1 2026, up 26.7% year-over-year from -$35.8 million in Q1 2025, and up 16.73% quarter-over-quarter from -$54.4 million in Q4 2025.
Perrigo (PRGO) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Cash from Financing Activities data on file, last reported at -$45.3 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$45.3 million, up 26.7% year-over-year; the trailing twelve-month figure through Mar 2026 was -$204.0 million (up 66.69% YoY), and the FY2025 annual result was -$220.5 million, up 63.91% from the prior year.
- Cash from Financing Activities improved to -$45.3 million in Q1 2026 per PRGO's latest filing, from -$54.4 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $653.3 million in Q3 2024 and troughed at -$1.2 billion in Q4 2024.
- A 5-year average of -$37.8 million and a median of -$49.8 million in 2024 frame the typical range for Cash from Financing Activities.
- On a YoY basis, Cash from Financing Activities climbed as much as 1608.78% in 2024 and fell as far as 2487.67% in 2024.
- A 5-year view of Cash from Financing Activities shows it stood at -$42.5 million in 2022, then retreated by 4.94% to -$44.6 million in 2023, then tumbled by 2487.67% to -$1.2 billion in 2024, then surged by 95.29% to -$54.4 million in 2025, then increased by 16.73% to -$45.3 million in 2026.
- Business Quant data shows PRGO's Cash from Financing Activities at -$45.3 million in Q1 2026, -$54.4 million in Q4 2025, and -$50.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -77.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -11.62 Mn |
| 10 | Perrigo | 1.55 Bn | 1.19 Bn | 325.50 Mn | -45.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | -45.30 Mn |
| Mar 28, 2026 | -45.30 Mn |
| Dec 31, 2025 | -54.40 Mn |
| Dec 31, 2025 | -54.40 Mn |
| Sep 27, 2025 | -50.30 Mn |
| Sep 27, 2025 | -50.30 Mn |
| Jun 28, 2025 | -54.00 Mn |
| Jun 28, 2025 | -54.00 Mn |
| Mar 29, 2025 | -61.80 Mn |
| Mar 29, 2025 | -61.80 Mn |
| Dec 31, 2024 | -1.15 Bn |
| Dec 31, 2024 | -1.15 Bn |
| Sep 28, 2024 | 653.30 Mn |
| Sep 28, 2024 | 653.30 Mn |
| Jun 29, 2024 | -49.80 Mn |
| Jun 29, 2024 | -49.80 Mn |
| Mar 30, 2024 | -60.40 Mn |
| Mar 30, 2024 | -60.40 Mn |
| Dec 31, 2023 | -44.60 Mn |
| Dec 31, 2023 | -44.60 Mn |